CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS

  01 July 2020

CARB-X announced that it is awarding up to US$1.82 million to Eligo Bioscience in Paris, France, with additional funding for a total award of up to US$7.05 million if project milestones are met, for the development of a new generation of highly-specific antimicrobials to prevent multi-drug-resistant bacterial infections in organ transplant patients. Eligo’s bacteriophage- and CRISPR-based therapeutics are designed to selectively eliminate extended-spectrum beta-lactamase-producing (ESBL) and Carbapenem-resistant E. coli and K. Pneumoniae (CRE) from the microbiome of transplant patients before their procedure, thereby preventing the onset of these often-fatal infections.

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!